Commentary: When to start and what to use in children-recommendations and rationale

AIDS

Volumn 28, Issue SUPPL. 2, 2014, Pages

  Siberry, George ^a   Tindyebwa, Denis ^b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b ANECCA   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CHILDHOOD DISEASE; DISEASE COURSE; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; VIRUS LOAD; HIV INFECTIONS; PREVENTION AND CONTROL; VERTICAL TRANSMISSION;

ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL;

EID: 84901436126     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000241     Document Type: Note

References (10)

1. WorldHealthOrganization.Consolidated guidelines onthe use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013, http://whqlibdoc.who.int/publica tions/2010/9789241599764-eng.pdf. [Accessed 26 January 2014]
2. Siegfried N, Davies MA, Penazzato M, Muhe LM, Egger M. Optimal time for initiating antiretroviral therapy (ART) in HIVinfected, treatment-naive children aged 2 to 5 years old. Cochrane Database Syst Rev 2013; 10:CD010309.
3. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIVinfected infants. N Engl J Med 2008; 359:2233-2244.
4. World Health Organization. What ARV regimen to start with in children older than or equal to three years of age? Geneva: World Health Organization; 2013, http://apps.who.int/iris/bit stream/10665/90744/1/WHO-HIV-2013.27-eng.pdf. [Accessed 26 January 2014]
5. Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams EJ. Optimization of antiretroviral therapy in HIV-infected children under 3 years of age: a systematic review. AIDS 2014; 28 (Supp 2):S137-S146.
6. Palumbo P, Lindsey JC, HughesMD, Cotton MF, Bobat R, Meyers T, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010; 363:1510-1520.
7. Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, Kamthunzi P, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 2012; 366:2380-2389.
8. Bristol-Myers Squibb Company. Sustiva [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; May 2013.
9. Coovadia A, Abrams EJ, Stehlau R, Meyers T, Martens L, Sherman G, et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA 2010; 304:1082-1090.
10. ARROW trial team. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet 2013; 381:1391-1403.